PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Fiche publication
Date publication
avril 2023
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MANSI Laura, Dr FAVIER Laure
Tous les auteurs :
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, Moubarak M, Rivoirard R, Polastro L, Favier L, You B, Berton D, de la Motte Rouge T, Mansi L, Abdeddaim C, Prulhiere K, Lancry Lecomte L, Provansal M, Dalban C, Ray-Coquard I
Lien Pubmed
Résumé
PARP inhibitors (PARPi) have revolutionized the management of high-grade epithelial ovarian cancer (HGOC) treatment. However, a significant number of patients relapse or progress under PARPi, leading to the introduction of a new line of systemic therapy such as chemotherapy. In patients with a limited number of metastatic sites at progression, -referred to as an oligometastatic progression- a potential indication for local therapy followed by re-introduction or continuation of PARPi treatment rather than initiating a new line of chemotherapy could be proposed. However, the impact of such strategies on progression free survival (PFS) in these patients remains unknown.
Mots clés
High-grade epithelial ovarian cancer, Local therapy, Oligometastatic progression, PARP inhibitors
Référence
Gynecol Oncol. 2023 04 25;173:98-105